Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents results from a Phase Ib/II study (NCT04086264) of pivekimab sunirine, a CD123-targeting antibody-drug conjugate, plus venetoclax and azacitidine in unfit patients with newly diagnosed acute myeloid leukemia (AML). He highlights a robust complete remission rate, particularly in TP53 wild-type disease, a manageable safety profile, and mentions the ongoing randomized Phase II/III REVIVAL trial (NCT07581002). This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) 2026, held in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.